Why Launch is Not Shipment

I thought we had a successful launch. We had regulatory clearance, product was shipping, and revenue had started to come in. On the surface, everything looked like it was working exactly as planned.

Six months later, we had inventory sitting in distributor warehouses and no real adoption. Clinicians weren’t using the product, and the early momentum we thought we had built wasn’t translating into anything that would last.

We had confused shipment with launch. That mistake cost us time, money, and momentum.

The Shipment Trap

This is how most medtech launches actually play out. Teams spend years developing the product, navigating regulatory pathways, and preparing for commercialization. When approval finally comes, there’s a rush to ship, to get product into the market, and to start generating revenue.

The product is technically available. Orders come in. Shipments go out. On paper, it looks like progress.

But then something subtle happens. A few clinicians try the product once. Most go back to what they already know. Usage doesn’t build. It stalls quietly, often without anyone realizing it at first. From a distance, the numbers can still look acceptable, but underneath, nothing is compounding.

This is where most teams get misled. Shipment feels like progress. It’s the most dangerous signal in the business, because it creates the illusion that the launch is working while adoption is quietly failing underneath.

Adoption Is the Business

In medtech, launch doesn’t happen when the product ships. It happens when a clinician chooses to use it again.

That second use is the moment the business actually begins. It’s the point where the product moves from being available to being part of clinical behavior. Everything before that is setup.

What Most Teams Track (and Why It Fails)

Most companies focus on units shipped, revenue booked, and the number of accounts opened. These metrics are easy to measure and easy to report, which is why they dominate dashboards and board conversations.

The problem is that they are all lagging indicators. They tell you what has already happened, not what is about to happen. By the time they start to move in the wrong direction, you are already behind.

This is why so many launches look healthy for a quarter or two and then stall. The signals that something is wrong were there early, but they weren’t the signals anyone was watching.

What Actually Predicts Success

The indicators that matter show up earlier and are harder to measure, but they are far more predictive.

Time to first case tells you whether your onboarding and training are working. If it takes too long from delivery to use, something is broken in the process.

Repeat usage within 30 days is even more telling. If a clinician doesn’t come back to your device within a month, you have likely already lost them. They are not gradually adopting it; they have made a decision.

Training competency matters as well. It is not enough that training occurred. The question is whether the clinician can use the device confidently without support.

And then there is the presence of clinical champions. These are not passive users, but people who actively advocate for the product inside the account. Without them, adoption rarely scales.

Together, these signals tell you whether adoption is forming or failing long before revenue reflects it.

The 30 / 60 / 90 Reality

Launch is not an event. It is a 90-day system that needs to be actively managed.

In the first 30 days, the focus is activation. The goal is to turn shipment into usage. If devices are sitting unopened, you do not have a launch. You have inventory.

Between days 31 and 60, patterns begin to emerge. You start to see where adoption is taking hold and where it is stalling. Objections repeat. Friction becomes visible. This is the window where adjustments should be made, although most teams fail to act quickly enough.

By days 61 to 90, the outcome is clear. Either adoption is forming, or it is not. At that point, no amount of additional marketing will compensate for a lack of real usage.

Distribution Is Not Adoption

One of the most common mistakes is assuming that distribution equals success. Distribution gives you access to the market. It gets your product into hospitals and onto approved vendor lists.

But access is not the same as usage. You can have contracts, coverage, and product sitting in hundreds of hospitals and still have no real adoption.

Adoption is fundamentally about behavior change. It requires clinicians to alter habits, trust new outcomes, and integrate a new solution into their workflow. That only happens with the right combination of evidence, training, reinforcement, and internal advocacy.

Distribution does not create that. It simply creates the opportunity for it to happen.

The Real Cost

The cost of confusing shipment with launch is not just wasted inventory or missed projections. The real cost is time.

Teams spend months believing they are progressing when they are not. By the time the lack of adoption shows up in revenue, the opportunity to correct course early has already passed.

And time is the one resource you cannot recover.

What Changed for Us

We stopped treating launch as a shipment milestone and started building around adoption instead.

That meant tracking leading indicators on a weekly basis, intervening early when signals were off, and prioritizing clinical usage over early revenue. It also meant being willing to say no to expansion when we did not have the infrastructure to support adoption properly.

Because scaling something that is not being used does not fix the problem. It amplifies it.

What This Means for You

If you are preparing for a launch, the most important question is not how quickly you can ship. It is whether you understand how adoption will actually happen.

Do you know how long it takes to reach a first case? Do you know who your clinical champions are? Do you know which accounts are not using your product anymore?

If you cannot answer those questions, you do not have a launch. You have exposure.

The Long Game

Medtech does not reward shipment. It rewards adoption.

Shipment gives you access, but adoption gives you a business. It is what turns early activity into something that compounds.

And if clinicians are not coming back to your device within 30 days, you have likely already lost the account.